Fresh Tracks Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Positive topline results from single and multiple ascending dose parts of the Phase 1 study of FRTX-02 support its continued development as a potential first-in-class, once-daily oral treatment for atopic dermatitis and/or other autoimmune diseases
Related news for (FRTX)
- Fresh Tracks Therapeutics Announces Dissolution, Initial Cash Distribution and Termination of Trading on the OTC Pink Market
- Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution
- Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company
- Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th
- Fresh Tracks Therapeutics Announces Plan to Hold New Special Meeting of Stockholders on February 15th